Centessa Pharmaceuticals plc (CNTA) Revenue History
Annual and quarterly revenue from 2020 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2021)
CNTA's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
CNTA Revenue Analysis (2020–2024)
As of March 1, 2026, Centessa Pharmaceuticals plc (CNTA) generated trailing twelve-month (TTM) revenue of $15.0 million. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, CNTA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $6.9 million in 2023.
Revenue diversification analysis shows CNTA's business is primarily driven by Lixivaptan (100%). With over half of revenue concentrated in Lixivaptan, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including REGN (+1.0% YoY), IMNM (-4.4% YoY), and CLDX (-78.6% YoY). Compare CNTA vs REGN →
Peer Comparison
Compare CNTA's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CNTACurrent | $15M | - | - | - | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | -100.0% | $0 | - | $-201,055,000 | - |
| 2023 | $6.9M | - | $6.9M | 100.0% | $-171,283,000 | -2499.4% |
| 2022 | $0 | - | $0 | - | $-212,263,000 | - |
| 2021 | $0 | - | $0 | - | $-374,867,000 | - |
| 2020 | $0 | - | $0 | - | $-10,440,000 | - |
See CNTA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CNTA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CNTA vs AGIO
See how CNTA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CNTA's revenue growth accelerating or slowing?
CNTA TTM revenue: $15M. YoY growth: N/A. 5-year CAGR: N/A.
What is CNTA's long-term revenue growth rate?
Centessa Pharmaceuticals plc's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is CNTA's revenue distributed by segment?
CNTA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2024 are available for download. Segment mix reveals concentration and diversification trends.